About ADARx Pharmaceuticals
ADARx Pharmaceuticals is a company based in San Diego (United States) founded in 2019 by Zhen Li. ADARx Pharmaceuticals has raised $352.5 million across 7 funding rounds from investors including BlackRock, T. Rowe Price and Marshall Wace. The company has 44 employees as of December 31, 2022. ADARx Pharmaceuticals offers products and services including RNA Medicines. ADARx Pharmaceuticals operates in a competitive market with competitors including Poseida Therapeutics, Senti Biosciences, CRISPR Therapeutics, WhiteLab Genomics and OXGENE, among others.
- Headquarter San Diego, United States
- Employees 44 as on 31 Dec, 2022
- Founders Zhen Li
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Adarx Pharmaceuticals Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$352.5 M (USD)
in 7 rounds
-
Latest Funding Round
$200 M (USD), Series C
Aug 02, 2023
-
Investors
BlackRock
& 17 more
-
Employee Count
44
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ADARx Pharmaceuticals
ADARx Pharmaceuticals offers a comprehensive portfolio of products and services, including RNA Medicines.
Treatments that silence disease-causing genes via RNA technology
People of ADARx Pharmaceuticals
Unlock access to complete
Unlock access to complete
Funding Insights of ADARx Pharmaceuticals
ADARx Pharmaceuticals has successfully raised a total of $352.5M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $200 million completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ADARx Pharmaceuticals
ADARx Pharmaceuticals has secured backing from 18 investors, including venture fund and institutional investors. Prominent investors backing the company include BlackRock, T. Rowe Price and Marshall Wace.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are focused on pharmaceutical, biotechnology, and medical sectors.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Venture capital is provided to healthcare startups by Commodore Capital.
|
Locked | Locked | Locked |
Investor details for ADARx Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ADARx Pharmaceuticals
Investment portfolio details for ADARx Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ADARx Pharmaceuticals
Detailed financials for ADARx Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Adarx Pharmaceuticals Comparisons
Peer comparison for ADARx Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ADARx Pharmaceuticals
ADARx Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Poseida Therapeutics, Senti Biosciences, CRISPR Therapeutics, WhiteLab Genomics and OXGENE, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Cell-based therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Solutions for genetic diseases are developed using CRISPR-Cas9 genome editing.
|
|
| Locked | Locked | Locked |
AI platform for drug discovery and development is provided.
|
|
| Locked | Locked | Locked |
Provider of a platform for mammalian cell engineering
|
Detailed competitors of ADARx Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Adarx Pharmaceuticals
Complete news archive for ADARx Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ADARx Pharmaceuticals
ADARx Pharmaceuticals was founded in 2019 and raised its 1st funding round 1 year after it was founded.
ADARx Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Zhen Li is the current CEO of ADARx Pharmaceuticals. They have also founded this company.
ADARx Pharmaceuticals is a funded company, having raised a total of $352.5M across 7 funding rounds to date.
As of Dec 31, 2022, the latest employee count at ADARx Pharmaceuticals is 44.
ADARx Pharmaceuticals was founded in 2019 in San Diego, United States. Genetic therapeutic solutions are developed to target and edit single point mutations on RNA transcripts. Precise modifications are made to nucleotide sequences in transcripts, enabling production of desired proteins from genomic templates. Operations focus on biotechnology applications for therapeutic editing, with leadership provided by co-founder and CEO Zhen Li.
ADARx Pharmaceuticals's top competitors include CRISPR Therapeutics, Senti Biosciences and Poseida Therapeutics.
ADARx Pharmaceuticals offers RNA Medicines.
ADARx Pharmaceuticals has 18 investors. Key investors include BlackRock, T. Rowe Price, Marshall Wace, Orbimed, and HBM Healthcare Investments.